Cargando…

In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study

The chemokine receptors CXCR1/2 play a key role in the aggressiveness of several types of cancers including head and neck squamous cell carcinomas (HNSCCs). In HNSCCs, CXCR1/2 signaling promotes cell proliferation and angiogenesis leading to tumor growth and metastasis. The competitive inhibitor of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montemagno, Christopher, Serrano, Benjamin, Durivault, Jérôme, Nataf, Valérie, Mocquot, François, Amblard, Régis, Vial, Valérie, Ronco, Cyril, Benhida, Rachid, Dufies, Maeva, Faraggi, Marc, Pagès, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374394/ https://www.ncbi.nlm.nih.gov/pubmed/34430714 http://dx.doi.org/10.1016/j.bbrep.2021.101098

Ejemplares similares

Targeting of the ELR+CXCL/CXCR1/2 Pathway Is a Relevant Strategy for the Treatment of Paediatric Medulloblastomas
por: Penco-Campillo, Manon, et al.
Publicado: (2022)

Quantitative analysis of (99m)Tc-pertechnetate thyroid uptake with a large-field CZT gamma camera: feasibility and comparison between SPECT/CT and planar acquisitions
por: Serrano, Benjamin, et al.
Publicado: (2023)

A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma
por: Montemagno, Christopher, et al.
Publicado: (2023)

New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments
por: Dufies, Maeva, et al.
Publicado: (2019)

Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
por: Montemagno, Christopher, et al.
Publicado: (2021)

COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome
por: Dietz, Matthieu, et al.
Publicado: (2020)

Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas
por: Dumond, Aurore, et al.
Publicado: (2021)

Synthetic accesses to biguanide compounds
por: Grytsai, Oleksandr, et al.
Publicado: (2021)

Recent Advances in Age-Related Macular Degeneration Therapies
por: Fabre, Marie, et al.
Publicado: (2022)

AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity
por: Brolih, Sanja, et al.
Publicado: (2018)

Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma
por: Pagnuzzi-Boncompagni, Marina, et al.
Publicado: (2021)

Experimental Models in Neovascular Age Related Macular Degeneration
por: Rastoin, Olivia, et al.
Publicado: (2020)

Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma
por: Dumond, Aurore, et al.
Publicado: (2021)

VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness
por: Ndiaye, Papa Diogop, et al.
Publicado: (2019)

Microvascular injuries, secondary edema, and inconsistencies in lung vascularization between affected and nonaffected pulmonary segments of non-critically ill hospitalized COVID-19 patients presenting with clinical deterioration
por: Maincent, Cécile, et al.
Publicado: (2022)

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
por: Montemagno, Christopher, et al.
Publicado: (2020)

Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
por: Hagege, Anais, et al.
Publicado: (2022)

SH3BGRL2, a new downregulated tumor suppressor in clear cell renal cell carcinomas
por: Dufies, Maeva
Publicado: (2020)

Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5
por: Giuliano, Sandy, et al.
Publicado: (2019)

Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
por: Montemagno, Christopher, et al.
Publicado: (2020)

Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine
por: Montemagno, Christopher, et al.
Publicado: (2020)

CXCR4 PET imaging of mantle cell lymphoma using [(68)Ga]Pentixafor: comparison with [(18)F]FDG-PET
por: Mayerhoefer, Marius E., et al.
Publicado: (2021)

Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?
por: Echavidre, William, et al.
Publicado: (2022)

COVID arm and PET/FDG imaging
por: Barriere, Jérôme, et al.
Publicado: (2021)

Imaging Inflammation in Atherosclerosis with CXCR4-Directed [(68)Ga]PentixaFor PET/MRI—Compared with [(18)F]FDG PET/MRI
por: Lu, Xia, et al.
Publicado: (2022)

Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future
por: Echavidre, William, et al.
Publicado: (2023)

FDG-PET in lymphoma
por: Meignan, Michel
Publicado: (2014)

PET-FDG: Impetus
por: Nanni, Cristina
Publicado: (2020)

The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma
por: Giuliano, Sandy, et al.
Publicado: (2014)

Disrupting glucose-6-phosphate isomerase fully suppresses the “Warburg effect” and activates OXPHOS with minimal impact on tumor growth except in hypoxia
por: de Padua, Monique Cunha, et al.
Publicado: (2017)

In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer
por: Montemagno, Christopher, et al.
Publicado: (2019)

Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies
por: Jaune, Emilie, et al.
Publicado: (2021)

The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5)
por: Cormerais, Yann, et al.
Publicado: (2018)

Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies
por: Guyot, Mélanie, et al.
Publicado: (2016)

FDG-PET and PET/CT - Part II
por: Takalkar, Amol M, et al.
Publicado: (2008)

FDG-PET in colorectal cancer
por: de Geus-Oei, Lioe-Fee, et al.
Publicado: (2006)

FDG-PET of Takayasu’s Arteritis
por: Shikino, Kiyoshi, et al.
Publicado: (2014)

FDG-PET/CT in lymphoma
por: D'souza, Maria M, et al.
Publicado: (2013)

FDG-PET and colon cancer
por: Miles, Ken
Publicado: (2015)

The Impact of Artificial Intelligence CNN Based Denoising on FDG PET Radiomics
por: Jaudet, Cyril, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v6ci9t59ge1iemthcsqj43i6ek